IRIS Research and Development

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, IRIS Research and Development sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting 1 completed upper half by trial count

IRIS Research and Development: 2 sponsored US clinical trials, 1 recruiting.

IRIS Research and Development sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Granulomatosis With Polyangiitis, with 1 trials.

Mid-pack sponsor footprint

IRIS Research and Development is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the IRIS Research and Development pipeline

1 recruiting of 2 indexed (50% open); 1 completed (50%).

Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).

Top condition: Granulomatosis With Polyangiitis (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

IRIS Research and Development: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

IRIS Research and Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share IRIS Research and Development1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
IRIS Research and Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

IRIS Research and Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this IRIS Research and Development page

2 registered trials is a research-attention snapshot, not an endorsement of IRIS Research and Development or any single study.

  • 1 of IRIS Research and Development's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Granulomatosis With Polyangiitis is the condition IRIS Research and Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Granulomatosis With Polyangiitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

IRIS Research and Development pipeline card: 2 registered trials from official public datasets.Report a data error.